Cargando…

Insulin detemir may be less efficacious in patients with nonalcoholic fatty liver disease and hypertriglyceridemia

Insulin detemir is commonly used in obese patients with diabetes mellitus as it is considered hepatoselective and causes less weight gain. We describe a relative lack of effectiveness of detemir in patients with significant NAFLD and hypertriglyceridemia, compared to isophane insulin. This may affec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whyte, Martin, Quaglia, Alberto, Hopkins, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706392/ https://www.ncbi.nlm.nih.gov/pubmed/26783443 http://dx.doi.org/10.1002/ccr3.458

Ejemplares similares

Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia
por: Zhang, Shujun, et al.
Publicado: (2017)

Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia: Erratum
Publicado: (2017)

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin
por: Cengiz, Eda, et al.
Publicado: (2012)

Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death
por: Paiva, Adriene A., et al.
Publicado: (2017)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Nonalcoholic fatty liver disease and insulin resistance in children
por: Song, Kyungchul, et al.
Publicado: (2023)

Reduced Efficacy of Insulin Detemir in Controlling Hyperglycemia during Pregnancy: An Interesting Case Report
por: Pande, Arun, et al.
Publicado: (2018)

Hypoadiponectinemia and Insulin Resistance are Associated with Nonalcoholic Fatty Liver Disease
por: Yoon, Dokyoung, et al.
Publicado: (2005)

Characteristics of hepatic insulin‐sensitive nonalcoholic fatty liver disease
por: Shigiyama, Fumika, et al.
Publicado: (2017)

Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver
por: Jelenik, Tomas, et al.
Publicado: (2017)

The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
por: Fujii, Hideki, et al.
Publicado: (2020)

Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease
por: Armandi, Angelo, et al.
Publicado: (2021)

Treatment of Severe Hypertriglyceridemia with Continuous Insulin Infusion
por: Rodríguez Santana, Yesica, et al.
Publicado: (2011)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
por: Philips, Jean-Christophe, et al.
Publicado: (2006)

Cerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
por: Tschritter, Otto, et al.
Publicado: (2007)

Insulin detemir for the treatment of obese patients with type 2 diabetes
por: Hollander, Priscilla A
Publicado: (2012)

Insulin Detemir in Pregnancy: A Small but Significant Step Forward?
por: McElduff, Aidan
Publicado: (2012)

The role of insulin detemir in overweight type 2 diabetes management
por: Demssie, Yared N, et al.
Publicado: (2009)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch, Jean-Pierre
Publicado: (2010)

Nutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
por: Conlon, Beth A., et al.
Publicado: (2013)

Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
por: Akhtar, Daud H., et al.
Publicado: (2019)

Nonalcoholic fatty liver disease and the risk of insulin-requiring gestational diabetes
por: You, Sang Youn, et al.
Publicado: (2021)

Heparin and Insulin for Hypertriglyceridemia-Induced Pancreatitis: Case Report
por: Jain, Deepika, et al.
Publicado: (2009)

Hypertriglyceridemia-Induced Pancreatitis With Rapid Response to Insulin Therapy
por: Soliman, Sara
Publicado: (2021)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
por: Thalange, Nandu, et al.
Publicado: (2016)

Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
por: Dongiovanni, P., et al.
Publicado: (2017)

The Efficacy of Intravenous Insulin Infusion in the Management of Hypertriglyceridemia-Induced Pancreatitis in a Rural Community Hospital
por: Sawalha, Khalid, et al.
Publicado: (2020)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

Sustained Treatment with Insulin Detemir in Mice Alters Brain Activity and Locomotion
por: Sartorius, Tina, et al.
Publicado: (2016)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

The Efficacy of Pharmacological Treatment in Pediatric Nonalcoholic Fatty Liver Disease
por: Cho, Taeshik, et al.
Publicado: (2012)

Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years
por: Kawanaka, Miwa, et al.
Publicado: (2020)

Hepatic Notch Signaling Correlates With Insulin Resistance and Nonalcoholic Fatty Liver Disease
por: Valenti, Luca, et al.
Publicado: (2013)

Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
por: Kawanaka, Miwa, et al.
Publicado: (2015)

Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease
por: Britton, Laurence, et al.
Publicado: (2018)

Interleukin‐32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance
por: Dali‐Youcef, Nassim, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease and Thrombocytopenia III: Its Association With Insulin Resistance
por: López-Trujillo, Miguel Antonio, et al.
Publicado: (2019)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_j1hmnkalq53o1i9q6grqh5s37l